

Technology Advisory Committee A Interests Register


Topic: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy (managed access review of TA620)

Publication Date: 05/07/2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Abdallah Al- Mohammad	Committee member	Financial	Professor Al-Mohammad has received honoraria for lectures from AstraZeneca, Janssen, Takeda and Pharmacosmos, honoraria for attending advisory boards with Novartis, Pharmacosmos and AstraZeneca and he is due to carry out research with Pfizer and possibly with both AstraZeneca and Novartis in 2023. Professor Al-Mohammad confirmed all the above were in cardiology and mainly in heart failure. None of them were related to this appraisal.	N/A	22.11.2022	N/A	It was agreed that his declaration would not prevent Professor Al-Mohammad from participating in discussions on this appraisal



Dr Steve Edwards	Committee member	Financial	Dr Edwards is a member of the EAG for this appraisal,	N/A	25.11.2022 16.02.2023	N/A	As a direct conflict Dr Edwards did not participate in discussion on this appraisal.
Professor Jonathan A Ledermann	Clinical expert	Direct financial and personal	Professor Ledermann has attended advisory boards and received lecture fees from GSK; AstraZeneca; Clovis Oncology; Eisai; MSD/Merck; Artios Pharma; Regeneron; VBL Therapeutics; Bristol Myers Squibb; Nuvation and has received research grants paid to the University from AstraZeneca; MSD/Merck. He is also clinical investigator on trials with niraparib, olaparib and rucaparib in recurrent ovarian cancer, Editor Gynaecological Cancer Track, ESMO Clinical Practice Guidelines and Past Vice President, ESGO.	N/A	10.06.2022	N/A	It was agreed that his declaration would not prevent Professor Ledermann from providing expert advice to the committee.
Dr Rebecca Bowen	Clinical expert	Direct financial	Dr Rebecca Bowen has received honoraria for presentations on BRCA/HRD testing and advisory boards from AstraZeneca.	N/A	11.06.2022	N/A	It was agreed that her declaration would not prevent Dr Bowen from providing expert advice to the committee.



Florence Wilks	Patient expert	Indirect interests	In the last 12 months Ovarian Cancer Action received £10,000 funding from GSK — to support national clinical service improvement policy work.	N/A	06.06.2022	N/A	It was agreed that her declaration would not prevent Florence from providing expert advice to the committee.
Rachel Downing	Patient expert	Indirect interests	In the last 12 months Target Ovarian received £10,000 funding from GSK in November 2021 for Target Ovarian Cancer's support line.	N/A	13.06.2022	N/A	It was agreed that her declaration would not prevent Rachel from providing expert advice to the committee